Related Experiment Video
Updated: Jul 6, 2025
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Cell division cycle 42 effector protein 4 inhibits prostate cancer progression by suppressing ERK signaling pathway
Xiaowen Zhang1, Tao Yu2, Guojun Gao3
1School of Life Science and Technology, Weifang Medical University, Weifang, China.
Abstract:
Prostate cancer (PCa) is the most common malignancy among men worldwide. The cell division cycle 42 effector protein 4 (CDC42EP4) functions downstream of CDC42, yet its role and molecular mechanisms in PCa remain unexplored. This study aimed to elucidate the role of CDC42EP4 in the progression of PCa and its underlying mechanisms. Bioinformatical analysis indicated that CDC42EP4 expression was significantly lower in PCa tissue compared to normal prostate tissue. Cellular phenotyping analysis suggested that CDC42EP4 markedly inhibited the proliferation, migration, and invasion of PCa cells. Xenograft tumor assays further demonstrated that CDC42EP4 suppressed the growth of PCa cells in vivo. Mechanistically, the study established that CDC42EP4 inhibited the ERK pathway in PCa cells. Additionally, the ERK pathway inhibitor PD0325901 was employed, revealing that PD0325901 significantly nullified the effects of CDC42EP4 on PCa cell proliferation, migration, and invasion. Collectively, our findings demonstrate that CDC42EP4 acts as a critical tumor suppressor gene, inhibiting PCa cell proliferation, migration, and invasion through the ERK pathway, thereby presenting potential targets for PCa therapy.
Insights
Cell division cycle 42 effector protein 4 (CDC42EP4) suppresses prostate cancer (PCa) growth by inhibiting cell proliferation, migration, and invasion. This tumor suppressor function is mediated through the ERK pathway, offering potential therapeutic targets for PCa.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Prostate cancer (PCa) is a leading global malignancy in men.
- The role of cell division cycle 42 effector protein 4 (CDC42EP4) in PCa pathogenesis is largely unknown.
- Understanding CDC42EP4's function is crucial for identifying novel therapeutic strategies.
Purpose of the Study:
- To investigate the role of CDC42EP4 in prostate cancer progression.
- To elucidate the molecular mechanisms underlying CDC42EP4's function in PCa.
- To evaluate CDC42EP4 as a potential therapeutic target for PCa.
Main Methods:
- Bioinformatical analysis of CDC42EP4 expression in PCa tissues.
- In vitro cellular phenotyping assays (proliferation, migration, invasion).
- In vivo xenograft tumor assays.
- ERK pathway inhibition studies using PD0325901.
Main Results:
- CDC42EP4 expression is significantly downregulated in PCa tissues compared to normal tissues.
- CDC42EP4 overexpression inhibits PCa cell proliferation, migration, and invasion.
- CDC42EP4 suppresses PCa tumor growth in vivo.
- CDC42EP4 exerts its tumor-suppressive effects by inhibiting the ERK pathway.
- Inhibition of the ERK pathway abrogates the anti-cancer effects of CDC42EP4.
Conclusions:
- CDC42EP4 functions as a tumor suppressor gene in prostate cancer.
- CDC42EP4 inhibits PCa progression via the ERK signaling pathway.
- Targeting the CDC42EP4-ERK axis presents a promising therapeutic avenue for PCa.
Related Concept Videos
02:34Inhibition of Cdk Activity
01:23Negative Regulator Molecules
01:27Molecular Factors Affecting Cell Division
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...
02:38Mitogens and the Cell Cycle
02:39Positive Regulator Molecules
02:23Abnormal Proliferation